AIIMS-Delhi Designated as WHO Global Network Site for Pandemic Preparedness

IMT News Desk
IMT News Desk
· 2 min read

AIIMS, Delhi, has been selected as one of the World Health Organization’s (WHO) global network sites for pandemic preparedness and emergency response under the Global Influenza Surveillance and Response System (GISRS).

During the Covid-19 crisis, WHO initiated the Unity Study network to enable rapid investigations during pandemics or epidemics caused by emerging or re-emerging pathogens. As one of only five sites in the WHO South-East Asia Region, AIIMS-Delhi will play a central role in response readiness, conducting prompt evaluations of critical public health tools and supplementing surveillance systems during emergencies.

The Unity Study protocols, developed by WHO, provide standardized research methods that can be implemented in both inter-pandemic periods and active outbreaks. These protocols facilitate the rapid collection and sharing of epidemiological and biological data, allowing for evidence-based public health policy and timely global responses.

Dr. Puneet Misra, Professor of Community Medicine at AIIMS, emphasized the ongoing need for such capabilities. He noted that the Covid-19 pandemic highlighted the value of generic, standardized data protocols across countries, making health systems more capable of managing large-scale emergencies.

The newly designated centre at AIIMS-Delhi will continue its work even outside of pandemic periods, contributing to broader public health actions, building capacity, and strengthening preparedness systems to ensure ongoing readiness for any future health emergencies.

Read Next

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk
DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 
News
June 11, 2026

DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 

DFE Pharma has earned its third consecutive Gold Medal from EcoVadis, the world leader in corporate sustainability assessments, in recognition of its strong performance in the four themes rated: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. This distinction places DFE Pharma in the top 5% of companies, reflecting the company’s focused efforts to […]
Article by: IMT News Desk
Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India
News
June 11, 2026

Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India

Oval Advanced Fertility Care and Merck Specialities Private Limited, the Indian healthcare arm of Merck KGaA, Darmstadt, Germany and a global leader in fertility sciences with decades of scientific leadership in reproductive medicine, have signed a strategic Memorandum of Understanding (MOU).   India’s IVF market, valued at approximately USD 2.35 billion in 2024, is projected […]
Article by: IMT News Desk
Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global
News
June 11, 2026

Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global

Bengaluru-based precision oncology startup 4baseCare has raised ₹128 crore in its ongoing Series B funding round to expand its hospital-linked genomics laboratory network globally and scale its AI-powered precision oncology platform, OncoTwin. The latest funding round, which follows a first close of ₹90 crore co-led by Ashish Kacholia and Lashit Sanghvi with participation from existing […]
Article by: IMT News Desk